Sponsors (2)
The bill directs substantial new funding and program changes to expand prevention, treatment, and support for substance use and behavioral health—potentially improving access and capacity—while increasing federal spending, administrative requirements, and some legal/privacy risks that could complicate implementation and unevenly affect access across states.
People with substance use disorders and communities nationwide will get substantially more support through expanded and newly authorized funding for prevention, treatment, first‑responder training, maternal/residential SUD care, peer/recovery services, and regional technical assistance, increasing capacity and access to services.
People at risk of overdose will have broader access to overdose‑detection tools and overdose‑reversal options (explicit permission for test strips in grants, broader language covering any FDA‑approved reversal agent) and HHS is required to consider rescheduling buprenorphine/naloxone, which could expand treatment options.
Behavioral‑health workforce shortages may ease because the bill increases loan repayment funding for SUD treatment providers and allows limited use of grant funds for participant transportation to work/training/recovery.
Taxpayers and the federal budget will face higher spending commitments because the bill substantially increases authorized funding across multiple programs through FY2026–2030, raising appropriation pressure or requiring offsets.
State, local, Tribal applicants, grantees and federal agencies will face new and expanded administrative, reporting, and compliance burdens (grant documentation, interagency workgroups, cybersecurity and REMS reporting, meetings, website updates), increasing costs and staff time.
Narrowing the pharmacy‑to‑practitioner delivery exception and tying delivery to REMS conditions may limit some delivery options, add monitoring/admin work for pharmacies and providers, and could delay patient access in settings that relied on broader prior interpretations.
Based on analysis of 8 sections of legislative text.
Updates and reauthorizes a wide set of federal public health activities addressing substance use, overdose prevention, treatment, recovery, and related mental health services through FY2026–2030. It raises or sets funding authorization levels for prevention, maternal and youth programs, peer and recovery supports, and workforce development; broadens program language from "opioids" to "overdose" or "other drug" in many places; requires new reports, guidance, and studies (including on 9-8-8 cybersecurity, at-home drug disposal, and approved opioid analgesics); and creates interagency coordination on fentanyl contamination. It also clarifies certain Controlled Substances Act exceptions for pharmacies and updates professional education language.
Introduced March 31, 2025 by Brett Guthrie · Last progress December 1, 2025